148 related articles for article (PubMed ID: 37811799)
1. A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
Kittai AS; Skarbnik A; Miranda M; Yong ASM; Roos J; Hettle R; Palazuelos-Munoz S; Shetty V; Ghia P
Am J Hematol; 2023 Dec; 98(12):E387-E390. PubMed ID: 37811799
[No Abstract] [Full Text] [Related]
2. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
3. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
[TBL] [Abstract][Full Text] [Related]
4. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
Khan Y; O'Brien S
Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
6. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
8. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
9. Acalabrutinib in chronic lymphocytic leukemia.
Martino EA; Bruzzese A; Vigna E; Iaccino E; Mendicino F; Lucia E; Olivito V; Filippelli G; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2023 Apr; 24(5):545-549. PubMed ID: 36943916
[No Abstract] [Full Text] [Related]
10. Acalabrutinib for relapsed chronic lymphocytic leukaemia.
Burki TK
Lancet Oncol; 2016 Feb; 17(2):e48. PubMed ID: 26710712
[No Abstract] [Full Text] [Related]
11. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
[TBL] [Abstract][Full Text] [Related]
15. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
16. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
17. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
18. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]